Climb Bio, Inc.
NASDAQ:CLYMBiotechnology
Healthcare
$9.30 +0.17%
+$0.02 today
- Market cap
- $546.27M
- Beta
- 0.10
- P/E (TTM)
- -14.7
- EPS (TTM)
- -$0.77
52W Low $1.17High $12.48
Volume 0.87M
Average 0.88M
Balance Sheet
Inspect the capital base behind the business.
Assets
$167.74M
FY 2025 · Annual
-22.8% YoYLiabilities
$7.27M
FY 2025 · Annual
+37.0% YoYEquity
$160.47M
FY 2025 · Annual
-24.3% YoYBalance Sheet
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 46.92M | 43.59M | 93.11M | 87.23M | 35.69M |
| Short-term Investments | 89.56M | 79.98M | 13.69M | 63.69M | 65.39M |
| Net Receivables | 6.52M | 6.49M | 2.46M | 1.12M | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 852K | 3.01M | 112K | 256K | 4.77M |
| Total Current Assets | 148.25M | 134.39M | 110.26M | 154.87M | 105.85M |
| Property, Plant & Equipment (Net) | 0 | 471K | 199K | 490K | 793K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 24.92M | 0 | 0 | 61.61M | 59.57M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 70K | 128K | 15K | 215K | 1.53M |
| Total Non-current Assets | 24.99M | 599K | 214K | 62.32M | 61.89M |
| Total Assets | 173.24M | 134.99M | 110.47M | 217.19M | 167.74M |
| Account Payables | 1.4M | 750K | 66K | 705K | 2.27M |
| Short-term Debt | 0 | 0 | 0 | 0 | 256K |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 138K | 31K | 2.57M |
| Total Current Liabilities | 6.03M | 6.1M | 2.83M | 4.93M | 6.98M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 7K | 0 | 22K | 0 | 0 |
| Total Non-current Liabilities | 7K | 180K | 37K | 375K | 285K |
| Total Liabilities | 6.04M | 6.28M | 2.87M | 5.31M | 7.27M |
| Common Stock | 3K | 3K | 3K | 7K | 5K |
| Retained Earnings | (75.62M) | (120.86M) | (155.98M) | (229.88M) | (289.73M) |
| Accumulated OCI | (123K) | (358K) | (2K) | 23K | 435K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 167.2M | 128.72M | 107.6M | 211.88M | 160.48M |
| Total Debt | 0 | 480K | 349K | 532K | 541K |
| Net Debt | (46.92M) | (43.11M) | (92.76M) | (86.7M) | (35.14M) |
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $8.4M |
| Short-term Investments | $101.2M |
| Other Current | $3.8M |
| Total Current Assets | $113.4M |
| PP&E (Net) | $697.0K |
| Long-term Investments | $36.7M |
| Other Non-current | $1.5M |
| Total Non-current Assets | $39.0M |
| Total Assets | $152.4M |
Analysis
Selected assets total $152.4M for Latest. The largest visible component is Short-term Investments at $101.2M, about 66.4% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13D/A | SC 13D/A filing | Nov 9, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 5, 2026 | |
| S-3ASR | S-3ASR filing | Nov 5, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 | |
| 8-K | Current report | Nov 5, 2026 |
How much cash does CLYM have?
Climb Bio, Inc. (CLYM) reported $35.69M in cash and equivalents in fiscal 2025.
How much debt does CLYM carry?
Climb Bio, Inc. (CLYM) reported $541,000.00 of total debt, with net debt of -$35.14M.
Continue the stock analysis
Jump to another research area for this company.